Therma Bright Inc. (THRM.V)

Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. Its products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. The company also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients. It serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.